Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic stem cell transplantation + inaticabtagene autoleucel
- Development stage
- Unknown
- Lead developer
- Juventas Cell Therapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This combination therapy consists of autologous hematopoietic stem cell transplantation (Auto-HSCT) followed by the infusion of inaticabtagene autoleucel (CNCT19), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Inaticabtagene autoleucel is an autologous CAR-T product utilizing a single-chain variable fragment (scFv) derived from the HI19α clone, with a 4-1BB costimulatory domain and a CD3-zeta signaling domain. The regimen is being evaluated for adult patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in complete remission, aiming to eliminate minimal residual disease (MRD) and reduce the risk of relapse. The CAR-T cells are typically administered approximately 7 days after the stem cell transplant to provide a targeted anti-leukemic effect during the post-transplant recovery phase.
- Brand names
- YORWIDA
- Other names
- Inati-celInaticabtagene autoleucelCD19-CARTCD-19-CARTCD 19-CART
02
Targets
Beyond the preview
Go deeper on autologous hematopoietic stem cell transplantation + inaticabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic stem cell transplantation + inaticabtagene autoleucel.